基因流生物科学公司在2026年初等待关键的老化试验结果,而视机器公司则实现利并获得了版权增长. Genflow Biosciences awaits key aging trial results in early 2026, while Seeing Machines achieved profitability and received a royalty boost.

基因流生物科学正在进入关键的2026年,预计在第一季度将揭开其狗老化试验的盲目,专注于通过甲基化钟,肌肉活检和线粒体功能来研究生物年龄. Genflow Biosciences is entering a pivotal 2026, with unblinding of its dog aging trial expected in Q1, focusing on biological age via methylation clocks, muscle biopsies, and mitochondrial function. 积极成果可能引发许可证交易和非增值筹资。 Positive results could trigger a licensing deal and non-dilutive funding. 该公司还在推进MASH输油管线,目标是预防先进的纤维化和肝癌。 The company is also advancing its MASH pipeline targeting advanced fibrosis and liver cancer prevention. 由于生产变化,Seeing Machines在2026年1月获得了一笔一次性版权费,从而提高了现金流和利能力. Meanwhile, Seeing Machines received a lump sum royalty payment in January 2026, triggered by a production change, boosting cash flow and profitability. 到2025年底,该公司实现了现金流量平衡,并记录了第一个盈利月,预计2026年下半年全年盈利。 The company achieved cash-flow breakeven by year-end 2025 and recorded its first profitable month, with full-year profitability expected in the second half of 2026. 它还在CES展示了先进的驾驶员监测技术。 It also showcased advanced driver monitoring tech at CES.